AIM VACCINE (06660): mRNA-based herpes vaccine has applied for clinical trials. T-cell immunity, IgG antibody titers, and membrane antigen fluorescent antibody titers are all significantly higher than commercially available recombinant subunit vaccines.

AIM VACCINE (06660) announced that the group is actively advancing the development of vaccine product pipelines in accordance with the established company strategy, utilizing the advantages of mRNA technology platform. Through continuous technical innovation, the group is rapidly advancing the research and development of mRNA vaccine products. The mRNA herpes zoster vaccine has recently been submitted for clinical approval to the Drug Evaluation Center (CDE) of the China Food and Drug Administration. In preclinical animal studies, third-party testing results show that the group's mRNA herpes zoster vaccine exhibits significantly higher levels of specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers compared to commercially available recombinant subunit control vaccines. The uniqueness of the herpes zoster virus lies in its lifelong latency after initial infection, with T cells mediating absolute immune protection. By enhancing specific T cell immunity, the mRNA vaccine works to prevent virus reactivation, control viral intracellular infections, and reduce the risk of herpes zoster development. This aligns with the advantages of mRNA vaccines, as they can effectively induce T-cell responses without the need for adjuvants, and without adjuvant-related safety risks. Currently, there are no approved mRNA herpes zoster vaccines on the market internationally, with a vaccination rate of only about 0.1% in the target population. There is a significant room for improvement. GSK's global sales of herpes zoster vaccines in 2023 are estimated to be around $4.286 billion. According to industry consultant Zhushi Consulting, it is projected that by 2030, the market size for herpes zoster vaccines in China will reach about RMB 20 billion, and globally, it will reach about $23.9 billion. Once this product is approved for sale, it will bring considerable performance growth to the group. The group has established a comprehensive quality management system for mRNA vaccines and GMP-compliant commercial-scale production workshops. The mRNA technology platform has been validated with human clinical trial data from tens of thousands of mRNA vaccine products. The group has streamlined the entire lifecycle processes of mRNA vaccine research and development, production, and can quickly achieve industrialization and commercialization of mRNA vaccine products after completing clinical trials.